Endpoint

Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial

CONSHOHOCKEN, PA and VANCOUVER, BC, March 23 /PRNewswire/ - Neuromed Pharmaceuticals, Inc. today announced positive results of a pivotal phase 3 clinical trial of its lead investigational drug, Exalgo (hydromorphone HCl) Extended-Release Tablets (CII) (previously NMED-1077 and OROS(R) Hydromorphon...

Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study

--Preliminary Data from Ongoing Study Shows Seven of 14 Evaluable Patients Achieved Objective Tumor Response by the End of Two Treatment Cycles-- --Bavituximab Has Now Produced Positive Early Results in All Three Ongoing Phase II Combination Therapy Cancer Trials-- TUSTIN, Calif., Feb. 1...

Lumension Expands Global Footprint, Extends Leadership in Endpoint Security and Unveils New Brand Identity

Solid 30 Percent Year-Over-Year Revenue Growth, Key Customer and Partner Wins Drive Strong 2008 Year End Results Scottsdale, Ariz. (PRWEB) February 4, 2009 -- Despite an economic environment that has proven to be a challenge for businesses large and small, the high-tech...

Lumension Provides Leading e-Commerce Company Proactive Endpoint Security at a High Return

The New Ogren Group study quantifies ROI of Lumension's integrated application whitelisting and vulnerability management solutions inside a real-world enterprise environment Scottsdale, Ariz. (PRWEB) December 16, 2008 -- Demonstrating the value automated tools that alig...

Lumension Security Announces General Availability of Sanctuary Endpoint Protection and Data Protection Suite to Safeguard Data and Privacy

Powerful solution enables business productivity and ensures high level of security by encrypting and protecting removal media, storage devices, and CD/DVD. Scottsdale, AZ (PRWEB) August 4, 2008 -- http://www.lumension.com/home.jsp?rpLeadSourceId=2006 [Lumension Securi...

Clinical Trial by Licensee Does Not Meet Primary Endpoint

PASADENA, Calif., July 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today announced its licensee, BioMS Medical Corp., and Eli Lilly and Company reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expan...

Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint

Preliminary Analysis Demonstrates a 20-Meter Improvement in Six-Minute Walk Distance (p<0.0006) Conference Call to be Held at 9:00 a.m. Eastern Time on November 1, 2007 SILVER SPRING, Md., Nov. 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR ...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...icating that blinatumomab had achieved the primary endpoint in a phase 2 clinical trial in the treatment of ALL patients. The primary endpoint of the trial was minimal residual disease (MRD) re... cycles of treatment. Achievement of this primary endpoint required that 5 of the 21 patients enrolled in the...

Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir

...D., Ph.D. "Nearly all surveyed physicians said that improvements in sustained virologic response in genotype 1-infected patients is the most important endpoint that will persuade them to use a novel treatment in place of currently-available therapies." The report also finds that 40 percent of surveyed ...

Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis

...methotrexate therapy. Three dose levels will be evaluated: a 70 mg dose, a 110 mg dose and a 150 mg dose, each administered once daily. The primary endpoint will be the ACR20, which is defined by the American College of Rheumatology (ACR) as a 20 percent improvement in symptoms associated with rheumatoid a...

Endpoint in Medical Technology

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis

INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing ...

Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US

CARLSBAD, Calif., May 17 /PRNewswire/ -- Essentialis Inc, a clinical stage pharmaceutical company, announced today that it met its primary endpoint of statistically significant triglyceride reduction in a 90-patient Phase 2b trial of DCCR in dyslipidemic patients. The study encompassed both patien...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

Top-line data indicate statistically significant improvement in ACR20 responses over placebo PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced that the MDX-1100 Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) rec...

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

- Favorable results for secondary endpoints support outcomes benefit HAYWARD, Calif., May 6 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that FRANCIS (Fewer Recurrent Acute coronary events ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With Standard Platelet Therapy KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE:...

VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial

Pioneering study uses quantitative imaging endpoints from MRI analyses ROCHESTER, N.Y., March 12 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP ), a leading provider of quantitative imaging for clinical trials, today announced that BioSyntech Inc., a Canadian medical device co...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

MOUNTAIN VIEW, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced positive results from its second Phase 3 clinical trial of AZ-004 (Staccato(R) loxapine). This Phase 3 clinical trial was conducted in patients with bipolar disorder experiencing...

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia

LA JOLLA, Calif., Dec. 2 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome. NGX267 met the primary end...

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson...

More>>

Endpoint in Medical Products

AST (SGOT) Reagent (Colorimetric, Endpoint Procedure)

Description: For the quantitative colorimetric determination of AST (SGOT) in serum....
Company:Teco Diagnostics

ALT (SGPT) Reagent (Colorimetric, Endpoint Method)

Description: Alanine Aminotransferase (ALT) reagent is used for the quantitative determination of alanine aminotransferase (Glutamate pyruvate transaminase, SGPT) in human serum....
Company:Teco Diagnostics

Endpoint™ Silicone Double Pigtail Stent Sets

Description:... Used for temporary internal drainage from the ureteropelvic junction to the bladder. endpoint stents feature closed ends and are designed for open surgical and optional one-pass endoscopic placement. Supplied sterile in peel-open packages. Inte...
Company:Cook Urological

Lambda Fluoro 320

Description:... Flexible and sensitive fluorescence/luminescence microplate reader for endpoint and kinetic...
Company:MWG Biotech

ViewPoint CK System (Conductive Keratoplasty)

Description:...ropia between +0.75 D and +3.00 D or presbyopic patients who would benefit from a spherical treatment of between 1.00 D and 2.25 D to achieve a myopic endpoint of between -1.00 D and -2.00 D in their non-dominant eye to temporarily improve near vision. CK is unique in that it uses radiofrequency (RF) instea...
Company:Refractec, Inc.

Insulin Jumbo EIA Diabetes and Obesity Markers 008-10-1113-99

Description:...benzidine (TMB). The reaction is stopped by adding acid. The colorimetric endpoint is read spectrophotometrically.The ALPCO Insulin ELISA is a solid phase two...benzidine (TMB). The reaction is stopped by adding acid. The colorimetric endpoint is read spectrophotometrically....
Company:ALPCO Diagnostics

C-Peptide EIA Diabetes and Obesity Markers 008-10-1136-01

Description:...dy. The bound conjugate is detected by reaction with 3,3',5,5'-tetramethylbenzidine (TMB). The reaction is stopped by adding acid. The colorimetric endpoint is read spectrophotometrically....
Company:ALPCO Diagnostics

Insulin EIA Diabetes and Obesity Markers 008-10-1113-01

Description:...dy. The bound conjugate is detected by reaction with 3,3',5,5'-tetramethylbenzidine (TMB). The reaction is stopped by adding acid. The colorimetric endpoint is read spectrophotometrically....
Company:ALPCO Diagnostics

Ultrasensitive C-Peptide EIA Diabetes and Obesity Markers 008-10-1141-01

Description:...ibody. The bound conjugate is detected by reaction with 3,3',5,5'-tetramethylbenzidine (TMB). The reaction is stopped by adding acid. The colorimetric endpoint is read spectrophotometrically....
Company:ALPCO Diagnostics

Insulin Ultrasensitive EIA Diabetes and Obesity Markers 008-10-1132-01

Description:...dy. The bound conjugate is detected by reaction with 3,3',5,5'-tetramethylbenzidine (TMB). The reaction is stopped by adding acid. The colorimetric endpoint is read spectrophotometrically....
Company:ALPCO Diagnostics

Endpoint in Medical Definition

Surrogate markers

...as been suggested that this article or section be merged into Surrogate endpoint . ( Discuss ) A surrogate marker (or surrogate end point ) is term us...ive in reducing death from heart disease. "Death from heart disease" is the endpoint of interest, but "cholesterol" is the surrogate marker. Examples of other...

Endpoint in Medical Dictionary

Sphincter

...tments, and other medical ... Sphincter : A ring-shaped muscle that relaxes or tightens ... Sphincter -saving surgery represents a debatable endpoint for neoadjuvant ... Sometimes sphincter function in patients submitted to low-anterior resection is ... RECTAL SPHINCTER REPAIR ... The artifi...

Node

...lant stem where a leaf is attached ... In communication networks, a node is a connection point, either a redistribution point or a communication endpoint . The definition of a node depends on the network and protocol layer referred to. A physical network node is an active electronic device that is a...

Hemostasis

...asis (the cessation of blood loss from a ... Primary hemostasis . vWF ... Hemostasis . Coagulation (Fibrinolysis) · Clot ... Primary efficacy endpoint will be time to hemostasis . ... Chitosan dressing provides hemostasis in swine femoral arterial injury model. ... Vascular Obstruction, ...

Endpoint in Biological News

Mental fatigue can affect physical endurance

...vel in both the fatigued and non-fatigued trial. However, mentally fatigued participants started at a higher level of perceived effort and reached the endpoint sooner. The cardio-respiratory and musculo-energetic measurements did not vary between the two trials when compared at specific points in time. Howev...

Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections

...d of therapy, at the test-of-cure (TOC) visit (7 to 14 days post treatment) and at a late follow-up visit 7 to14 days after the TOC visit. The primary endpoint was the comparative clinical cure rates of iclaprim and linezolid at the TOC visit in the ITT and PP populations. The most commonly reported advers...

Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants

...ting a single-blind, placebo controlled, dose-escalating Phase 2 study of inhaled carbon monoxide in patients receiving renal transplants. The primary endpoint of the study is to evaluate the safety and tolerability of increasing carbon monoxide dose levels when administered as an inhaled gas to kidney transp...

Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants

...ting a single-blind, placebo controlled, dose-escalating Phase 2 study of inhaled carbon monoxide in patients receiving renal transplants. The primary endpoint of the study is to evaluate the safety and tolerability of increasing carbon monoxide dose levels when administered as an inhaled gas to kidney transp...

CMV infections affect more than just patients with compromised immune systems, researchers find

...might simply be a marker, rather than a cause," Limaye explained. "Because of that, we need to test the theory that by treating CMV we can improve the endpoint -- the length of stay in the hospital." If the planned clinical trial shows that treatment can cut down on CMV reactivation and reduce hospital sta...

Findings released from 1 of the largest percutaneous coronary intervention trials ever

...or adverse cardiovascular events (death, reinfarction, stroke or ischemic target vessel revascularization) or major bleeding at 30 days. The secondary endpoint was major adverse cardiovascular events at 30 days. Those patients receiving bivalirudin within 30 days had significantly reduced net clinical adverse...

HGS announces positive Phase 2 LymphoStat-B at ACR meeting

... and, most importantly, by the response rate chosen as the primary efficacy endpoint of the Phase 3 trials. We are encouraged by the continued improvement in t... 54% in the combined patient response rate selected as the primary efficacy endpoint of the Phase 3 trials. Among serologically active subjects who completed 1...

Positive results for airway bypass

...ients with emphysema are currently limited and generally result in anguished patients and frustrated physicians. The prospectively-defined primary endpoint of this feasibility study was a reduction in residual volume (RV, the amount of air remaining in the lungs after full exhalation) at 6 months. The goa...

Boston University biomedical engineers find chink in bacteria's armor

...antibiotics. Theres an underlying pathway beyond the drug interacting with the target, said graduate student and lead author Michael Kohanski, and the endpoint of this pathway is excessive free radical production. Free radicals -- such as hydroxyl or superoxide radicals -- are molecules that carry a free,...

Plastic that degrades in seawater could be boon for cruise industry and others

...tudy design, execution, and report." He continues, "Perhaps most importantly, the authors chose neonatal morbidity, a ‘health outcome,?as the primary endpoint instead of a surrogate such as days gained or percent of births before 32 or 35 weeks of gestation."...

Endpoint in Biological Technology

SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia

KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that its investigational agent SAPHRIS(R) (asenapine) met the primary endpoint over one year of treatment in an extension study in patients with predominant, persisten...

Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study

-Preliminary Data Show Seven of 17 Evaluable Patients Achieved an Objective Tumor Response by End of Four Treatment Cycles- TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported that its lead product candidate bavituximab achieved th...

Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery

SOUTH SAN FRANCISCO, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV ) today announced top-line results showing that the Phase 3 trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug candidate, achieved its primary efficacy endpoint of reducing post-surgica...

Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study

CALGARY, Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today that it has exceeded the primary statistical endpoint in its multi-centre Phase 2 clinical trial to evaluate the intravenous administration of REOLYSIN(R) in patients with var...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

- Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the ACHIEVE 2/3 trial in patients with genotypes 2 and 3 chronic hepatitis C - - Patients receiving 900-mcg Albuferon had comparable rates of serious adverse events, seve...

EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial

Phase 2 Randomized Study Under Consideration ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has met t...

Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial

KENILWORTH, N.J., Oct. 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that its novel psychopharmacologic agent asenapine has met the primary endpoint in a long-term schizophrenia relapse prevention trial. Asenapine, which is administered as a fast-dissol...

OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer

Data presented at the 2008 Genitourinary Cancers Symposium VANCOUVER, Feb. 15 /PRNewswire/ - OncoGenex Technologies Inc. announced today that the Company's lead cancer drug candidate, OGX-011, also referred to as custirsen, was well-tolerated in combination with either docetaxel or mito...

012 Smile.Communications Receives License to Provide Endpoint Network Services

Enables Company to Provide Complete End-to-End Communications Systems to Enterprise Customers PETACH TIKVA, Israel, January 22 /PRNewswire-FirstCall/ -- 012 Smile.Communications (NASDAQ Global Market and TASE: SMLC), a growth-oriented provider of communication services...

Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint

Company to host conference call Today, Monday, March 10, 2008 at 8:30am NEW YORK, March 10 /PRNewswire-FirstCall/ -- On Friday, March 7, 2008, Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the t...

Endpoint in Biological Products

bacterial endotoxin Chromogenic Assay Kit from Cell Sciences

Description:... LAL Chromogenic endpoint assay...
Company:Cell Sciences

ABTS™ Chromophore from Calbiochem

Description:...erall performance in ELISA. ABTS ™ develops intense blue-green color that can be measured at 405 nm to 410 nm. May be used for both kinetic and endpoint reactions. CAS 30901-67-0, M.W. 514.6. ...
Company:Calbiochem

LUMIstar OPTIMA Microplate Reader from BMG LABTECH

Description:...n select well-mode for fast injections and as short as 20 ms for interval time. Choose plate-mode for glow reactions that have longer kinetic times or endpoint test runs. Either way, an assay can be defined with up to 250 kinetic points at specified time intervals down to the millisecond range. Top and bottom...
Company:BMG LABTECH

BD Pathway Bioimager from BD Biosciences - Bioimaging

Description:... The BD Pathway Bioimager is an automated, confocal, real-time, single cell kinetic and endpoint imaging system that has been integrated into a single, compact unit. The BD Pathway was designed to provide high-resolution, automated confocal imagi...
Company:BD Biosciences - Bioimaging

Endpoint in Biological Definition

Enzyme

...ductase : participates in the electron transfer chain by reducing cytochrome c and pumping protons across the membrane Cytochrome c oxidase : endpoint of the electron transfer chain, where oxygen is reduced to water Cytochrome c peroxidase takes reducing equivalents from cytochrome c and redu...